Post Profile






Saxagliptin and saxagliptin/metformin in type 2 diabetes: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) The presented analyses of the SAVOR-TIMI 53 study were unsuitable for conclusions on positive or negative effects in comparison with the appropriate comparator therapies.
read more

share

Related Posts


Idelalisib in second-line treatment for CLL: Added benefit again not proven

Academics / General Science : Science Codex

Already in 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with chronic l...

Added benefit of saxagliptin/metformin combination is not proven

Academics / General Science : Science Codex

The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Re...

Nalmefene for alcohol dependence: Added benefit not proven

Academics / General Science : ScienceDaily: Science Society

No added benefit can be derived from the indirect comparison presented in the drug manufacturer dossier, in particular because the studies on the appropriate comparator therapy were unsuitable, scientists say.

Propranolol in infantile hemangioma: Indication of major added benefit in some patients

Academics / General Science : Science Codex

The Institute for Quality and Efficiency in Health Care (IQWiG) investigated in a dossier assessment whether propranolol offers an added benefit in comparison with the appropriate comparator therapy in infants with proliferating inf...

Selexipag in pulmonary arterial hypertension: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The data in the dossier were unsuitable to show an added benefit: Comparator therapy and division of the population were inadequate.

Comments


Copyright © 2016 Regator, LLC